CUFinder

Amer Zeidan, MBBS, MHS

Amer Zeidan, MBBS, MHS

Yale University

H-index: 51

North America-United States

Contact Amer Zeidan, MBBS, MHS

About Amer Zeidan, MBBS, MHS

Amer Zeidan, MBBS, MHS, With an exceptional h-index of 51 and a recent h-index of 43 (since 2020), a distinguished researcher at Yale University, specializes in the field of Myelodysplastic syndromes, Acute myeloid leukemia, Bone marrow failure disorders.

His recent articles reflect a diverse array of research interests and contributions to the field:

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised …

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES …

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised …

Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute …

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia

Amer Zeidan, MBBS, MHS Information

University

Position

Associate Professor of Medicine

Citations(all)

9667

Citations(since 2020)

7875

Cited By

4245

hIndex(all)

51

hIndex(since 2020)

43

i10Index(all)

198

i10Index(since 2020)

168

Email

University Profile Page

Google Scholar

Amer Zeidan, MBBS, MHS Skills & Research Interests

Myelodysplastic syndromes

Acute myeloid leukemia

Bone marrow failure disorders

Top articles of Amer Zeidan, MBBS, MHS

PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

The Journal of clinical investigation

2024/2/1

Xue Han
Xue Han

H-Index: 1

Jun Wang
Jun Wang

H-Index: 10

Qi Wang
Qi Wang

H-Index: 13

Sang Won Lee
Sang Won Lee

H-Index: 10

Jun Lu
Jun Lu

H-Index: 0

Mina L Xu
Mina L Xu

H-Index: 14

Steven D Gore
Steven D Gore

H-Index: 42

Lieping Chen
Lieping Chen

H-Index: 78

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised …

The Lancet

2024/1/20

Qi Xia
Qi Xia

H-Index: 8

Libo Sun
Libo Sun

H-Index: 22

Ying Wan
Ying Wan

H-Index: 4

Fei Huang
Fei Huang

H-Index: 2

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES …

Leukemia Research Reports

2024/1/1

J Li
J Li

H-Index: 9

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised …

The Lancet Haematology

2024/1/1

Brian Leber
Brian Leber

H-Index: 35

Yong Hao
Yong Hao

H-Index: 12

Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective

2024/1/1

Amir T Fathi
Amir T Fathi

H-Index: 42

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute …

Annals of Hematology

2024/1

Rahul Ramaswamy
Rahul Ramaswamy

H-Index: 1

Wei Wei
Wei Wei

H-Index: 5

Steven D Gore
Steven D Gore

H-Index: 42

Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice

2024/1/29

Nilay Shah
Nilay Shah

H-Index: 61

Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia

Leukemia & Lymphoma

2024/4/22

Kishan K Patel
Kishan K Patel

H-Index: 5

Maximilian Stahl
Maximilian Stahl

H-Index: 20

George Goshua
George Goshua

H-Index: 7

Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del (5q) Lower-Risk …

2024/4/5

Libo Sun
Libo Sun

H-Index: 22

Ying Wan
Ying Wan

H-Index: 4

Fei Huang
Fei Huang

H-Index: 2

Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary …

2024/3/21

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUSMDS1): a randomised, double-blind, placebo …

The Lancet Haematology

2024/1/1

Mehmet Turgut
Mehmet Turgut

H-Index: 18

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)

Clinical Lymphoma Myeloma and Leukemia

2024/3/1

Anuj Shah
Anuj Shah

H-Index: 13

Anders Svensson
Anders Svensson

H-Index: 38

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Leukemia

2024/2/20

Anthony Stein
Anthony Stein

H-Index: 9

Maximilian Stahl
Maximilian Stahl

H-Index: 20

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid …

Blood Cancer Journal

2024/2/20

Anand Patel
Anand Patel

H-Index: 0

Yasmin Abaza
Yasmin Abaza

H-Index: 8

Guru Subramanian Guru Murthy
Guru Subramanian Guru Murthy

H-Index: 11

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country

JCO Global Oncology

2024/2

Abdalla Awidi
Abdalla Awidi

H-Index: 13

Tariq Aladily
Tariq Aladily

H-Index: 10

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and …

Blood

2023/11/28

John Koreth
John Koreth

H-Index: 47

Maximilian Stahl
Maximilian Stahl

H-Index: 20

Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia

2023/9/28

PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY

HemaSphere

2023/8/1

Min Che
Min Che

H-Index: 2

Tao Gu
Tao Gu

H-Index: 34

Hong Xiao
Hong Xiao

H-Index: 8

Argiris Symeonidis
Argiris Symeonidis

H-Index: 28

Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit Versus Epoetin Alfa (EA …

Blood

2023/11/28

Amit K Verma
Amit K Verma

H-Index: 5

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

HemaSphere

2023/8/1

Dhrubajyoti Pathak
Dhrubajyoti Pathak

H-Index: 1

See List of Professors in Amer Zeidan, MBBS, MHS University(Yale University)

Co-Authors

academic-engine

Useful Links

List of top 50 universities
List of top 100 universities
List of top 500 universities
Find Professors Email
Find Universities Email
CUFinder Academic Engine